Literature DB >> 6847419

Cerebral vasomotor responsiveness during 100% oxygen inhalation in cerebral ischemia.

S Nakajima, J S Meyer, T Amano, T Shaw, T Okabe, K F Mortel.   

Abstract

Cerebral vasoconstrictor responsiveness to 100% oxygen inhalation was measured in 149 subjects, including normal healthy volunteers and those with risk factors for cerebral arteriosclerosis (N = 87). Test results were compared among patients with hemispheric stroke and vertebrobasilar insufficiency (N = 62) with the 133Xe inhalation method. Normal volunteers without risk factors (N = 49), aged 25 to 86 years, showed symmetrical vasoconstriction. Asymptomatic subjects with risk factors (N = 38) and those with vertebrobasilar insufficiency (N = 25) had decreased hemispheric gray matter flow (Fg) values during rest, but vasoconstrictor responsiveness to 100% oxygen inhalation was not significantly reduced. In patients with acute hemispheric infarction, regional vasoconstrictor responsiveness to 100% oxygen inhalation was lost and/or paradoxically reversed; in patients with chronic hemispheric infarction, it was decreased. Testing vasomotor responses during hyperoxia is safe, clinically helpful, and demonstrates impaired vasomotor reactivity in infarcted regions.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6847419     DOI: 10.1001/archneur.1983.04050050039004

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  18 in total

1.  Endothelial dysfunction abrogates the efficacy of normobaric hyperoxia in stroke.

Authors:  Hwa Kyoung Shin; Fumiaki Oka; Ji Hyun Kim; Dmitriy Atochin; Paul L Huang; Cenk Ayata
Journal:  J Neurosci       Date:  2014-11-12       Impact factor: 6.167

2.  Cerebrovascular pressure reactivity and cerebral oxygen regulation after severe head injury.

Authors:  Matthias Jaeger; Erhard W Lang
Journal:  Neurocrit Care       Date:  2013-08       Impact factor: 3.210

Review 3.  The physiology behind direct brain oxygen monitors and practical aspects of their use.

Authors:  Eileen Maloney-Wilensky; Peter Le Roux
Journal:  Childs Nerv Syst       Date:  2010-04       Impact factor: 1.475

Review 4.  Hyperbaric oxygen therapy in acute stroke: is it time for Justitia to open her eyes?

Authors:  Milija D Mijajlovic; Vuk Aleksic; Nenad Milosevic; Natan M Bornstein
Journal:  Neurol Sci       Date:  2020-01-11       Impact factor: 3.307

5.  Dynamic functional cerebral blood volume responses to normobaric hyperoxia in acute ischemic stroke.

Authors:  Ona Wu; Jie Lu; Joseph B Mandeville; Yoshihiro Murata; Yasu Egi; Guangping Dai; John J Marota; Izzuddin Diwan; Rick M Dijkhuizen; Kenneth K Kwong; Eng H Lo; Aneesh B Singhal
Journal:  J Cereb Blood Flow Metab       Date:  2012-06-27       Impact factor: 6.200

6.  Cerebral hemodynamic effects of acute hyperoxia and hyperventilation after severe traumatic brain injury.

Authors:  Leonardo Rangel-Castilla; Lucia Rivera Lara; Shankar Gopinath; Paul R Swank; Alex Valadka; Claudia Robertson
Journal:  J Neurotrauma       Date:  2010-09-17       Impact factor: 5.269

Review 7.  Imaging the penumbra in acute stroke.

Authors:  Ramez R Moustafa; Jean-Claude Baron
Journal:  Curr Atheroscler Rep       Date:  2006-07       Impact factor: 5.113

8.  The effect of increased inspired fraction of oxygen on brain tissue oxygen tension in children with severe traumatic brain injury.

Authors:  Anthony A Figaji; Eugene Zwane; A Graham Fieggen; Andrew C Argent; Peter D Le Roux; Jonathan C Peter
Journal:  Neurocrit Care       Date:  2010-06       Impact factor: 3.210

Review 9.  Pathophysiology of ischaemic stroke: insights from imaging, and implications for therapy and drug discovery.

Authors:  R R Moustafa; J-C Baron
Journal:  Br J Pharmacol       Date:  2007-11-26       Impact factor: 8.739

10.  Normobaric hyperoxia improves cerebral blood flow and oxygenation, and inhibits peri-infarct depolarizations in experimental focal ischaemia.

Authors:  Hwa Kyoung Shin; Andrew K Dunn; Phillip B Jones; David A Boas; Eng H Lo; Michael A Moskowitz; Cenk Ayata
Journal:  Brain       Date:  2007-04-27       Impact factor: 13.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.